Pancreatic Cancer Research

ResearcherNanjing University of Chinese MedicineActive in the last 2 years

Fan Tong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0009-2192-3377; OpenAlex author ID A5122772081. Sources: OpenAlex.

Their work

Papers
7 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: none · 2026: 1 paper

Papers 7

  1. Personalized tumor-informed circulating tumor DNA monitoring for early detection of recurrence in postoperative pancreatic cancer. Co-author DOI 10.3389/fonc.2026.1745466↗
  2. Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical t… First author DOI 10.1007/s00262-024-03744-z↗
  3. First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: … First author DOI 10.1038/s41392-024-01857-6↗
  4. Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, pha… Co-author DOI 10.3389/fimmu.2024.1210859↗
  5. Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer. Co-author DOI 10.1080/21645515.2023.2178791↗
  6. Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report. Co-author DOI 10.3389/fimmu.2023.1277810↗
  7. Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort. Co-author DOI 10.1080/21645515.2022.2143154↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Juan Du · 5 shared papers, 2022–2024 · strength 0.90
  2. Baorui Liu · 5 shared papers, 2022–2024 · strength 0.86
  3. Huizi Sha · 4 shared papers, 2023–2026 · strength 0.81
  4. Changchang Lu · 3 shared papers, 2022–2024 · strength 0.52
  5. Xin Qiu · 3 shared papers, 2022–2024 · strength 0.52
  6. Qiao-Li Wang · 3 shared papers, 2022–2024 · strength 0.52
  7. Liang Qi · 2 shared papers, 2023–2024 · strength 0.37
  8. Jingjing Chen · 1 shared paper, 2026 · strength 0.26
  9. Juan Du · 1 shared paper, 2026 · strength 0.26
  10. Lu Zou · 1 shared paper, 2026 · strength 0.26
  11. Qin Wang · 1 shared paper, 2024 · strength 0.20
  12. Juan Liu · 1 shared paper, 2024 · strength 0.20
  13. Zhan Shi · 1 shared paper, 2023 · strength 0.17
  14. Juan Du · 1 shared paper, 2023 · strength 0.17
  15. Xiaoling Gong · 1 shared paper, 2022 · strength 0.14
  16. Yujie Zhou · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.